Effect of Rivrvoxaban on the Prevention of Deep Vein Thrombosis and Pulmonary Embolism

Phase 3

• Conditions: Condition 1: Deep Vein Thrombosis. Condition 2: Pulmonary Embolism.; Phlebitis and thrombophlebitis of other deep vessels of lower extremities Deep vein thrombosis; Pulmonary embolism; I80.2

• Registration Number: IRCT20181128041781N1
• Lead Sponsor: Sabzevar University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

All People over the Age of 20 Years who are Candidates for Anticoagulant Therapy

Exclusion Criteria

History of Hypersensitivity Reaction to either of the Two Drugs
Severe Bleeding
Pregnancy and Lactation
History of Recent Labor or any Recent Injury
Having Liver Disease or any other Disease that Leads to an Increased Risk of Bleeding.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Deep Vein Thrombosis. Timepoint: One Month after Receiving Treatment. Method of measurement: Examinations and Color Doppler Ultrasound.;Pulmonary Embolism. Timepoint: One Month after Receiving Treatment. Method of measurement: Examinations and Color Doppler Ultrasound.